JCA Readiness
Prepare for EU JCA with clarity and confidence.
The Challenge:
EU JCA is reshaping how evidence is planned and coordinated across teams and markets. For rare disease programmes, mandatory scope begins in 2028 – but the internal preparation that makes a real difference needs to start well before that. Many teams are beginning to ask what they need to have in place, and when. nd documentation.
Our Insight:
JCA is not just a regulatory process. It is a cross-functional coordination challenge. The teams best placed will be those who have clarified ownership, aligned global and EU perspectives, and embedded JCA thinking into how asset decisions are made – before formal timelines begin.
Our Solution:
Through RAREready™, our upstream JCA readiness framework, we help sponsors:
- align global, regional and affiliate teams around a shared upstream view
- clarify how JCA is likely to apply to their programmes and what that means in practice
- organise patient insight early, in a way that will hold up under joint assessment scrutiny
- build the internal conditions to act on JCA thinking consistently across functions
- coordinate effectively across EU markets without drifting into HTA territory
Patient Identification
Find and reach the right patients earlier.
The Challenge:
In rare disease, many patients remain undiagnosed or misdiagnosed for years.
Traditional recruitment and awareness approaches struggle to reach small, dispersed populations.
Our Insight:
Earlier identification requires more than data – it needs behavioural insight, digital fluency and a deep understanding of the diagnostic journey.
Our Solution:
We take an ethically grounded, precision-driven approach to understanding and reaching hidden populations:
- behaviour-based journey mapping (AI-supported)
- digital awareness and pathway segmentation
- co-designed outreach strategies with patient groups
- integration with advocacy, clinician and centre networks
Advocacy & Education
Co-create programmes that build trust and strengthen awareness.
The Challenge:
Many advocacy efforts feel fragmented or superficial, limiting their impact and making it harder to build trust in rare disease.
Our Insight:
Effective advocacy is co-created with communities, grounded in insight and supported by meaningful digital ecosystems.
Our Solution:
We help teams develop advocacy and education initiatives that resonate and deliver value:
- digital ecosystem and influence mapping
- co-created awareness and education programmes
- supportive literacy materials developed with patient groups
- practical tools for patients, caregivers and HCPs
Why Modular Matters
Our work is modular — designed so teams can engage with what is genuinely useful at each stage, rather than committing to a fixed programme upfront.
We integrate with internal teams, agencies and affiliates, working alongside established processes rather than adding to them. And we are clear throughout about where our work ends and where specialist partners in HEOR, regulatory and market access take over.
We are a focused, senior team. The people you speak to at the outset are the people who do the work.